PATINA: A randomized, open label, phase III trial to evaluate the efficacy and safety of palbociclib + Anti-HER2 therapy + endocrine therapy (ET) vs. anti-HER2 therapy + ET after induction treatment for hormone receptor positive (HR+)/HER2-positive metastatic breast cancer (MBC)

Annals of Oncology ◽

10.1093/annonc/mdy272.357 ◽

2018 ◽

Vol 29 ◽

pp. viii121 ◽

Cited By ~ 1

Author(s):

S. Loibl ◽

O. Metzger ◽

S.J. Mandrekar ◽

C. Mundhenke ◽

S. Seiler ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Phase Iii ◽

Induction Treatment ◽

Efficacy And Safety ◽

Her2 Positive ◽

Open Label ◽

Phase Iii Trial ◽

Hormone Receptor Positive ◽

Open Label Phase

Abstract OT3-02-07: PATINA: A randomized, open label, phase III trial to evaluate the efficacy and safety of palbociclib + anti-HER2 therapy + endocrine therapy (ET) vs. anti-HER2 therapy + ET after induction treatment for hormone receptor positive (HR+)/HER2-positive metastatic breast cancer (MBC)

10.1158/1538-7445.sabcs18-ot3-02-07 ◽

2019 ◽

Author(s):

O Metzger ◽

S Mandrekar ◽

S Loibl ◽

C Mundhenke ◽

S Seiler ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Phase Iii ◽

Induction Treatment ◽

Efficacy And Safety ◽

Her2 Positive ◽

Open Label ◽

Phase Iii Trial ◽

Hormone Receptor Positive ◽

Open Label Phase

Abstract OT3-05-07: PATINA: A randomized open label phase III trial to evaluate the efficacy and safety of palbociclib + anti HER2 therapy + endocrine therapy vs anti HER2 therapy + endocrine therapy after induction treatment for hormone receptor positive, HER2 positive metastatic breast cancer

10.1158/1538-7445.sabcs17-ot3-05-07 ◽

2018 ◽

Cited By ~ 1

Author(s):

O Metzger-Filho ◽

S Mandrekar ◽

S Loibl ◽

E Ciruelos ◽

L Gianni ◽

...

Keyword(s):

Endocrine Therapy ◽

Metastatic Breast ◽

Phase Iii ◽

Induction Treatment ◽

Efficacy And Safety ◽

Her2 Positive ◽

Open Label ◽

Phase Iii Trial ◽

Hormone Receptor Positive ◽

Open Label Phase

PATINA: A randomized open label phase III trial to evaluate the efficacy and safety of palbociclib + anti HER2 therapy + endocrine therapy vs anti HER2 therapy + endocrine therapy after induction treatment for hormone receptor positive, HER2-positive metastatic breast cancer

Annals of Oncology ◽

10.1093/annonc/mdx365.087 ◽

2017 ◽

Vol 28 ◽

pp. v107-v108

Author(s):

O. Metzger ◽

S. Mandrekar ◽

E. Ciruelos ◽

S. Loibl ◽

P. Valagussa ◽

...

Keyword(s):

Endocrine Therapy ◽

Metastatic Breast ◽

Phase Iii ◽

Induction Treatment ◽

Efficacy And Safety ◽

Her2 Positive ◽

Open Label ◽

Phase Iii Trial ◽

Hormone Receptor Positive ◽

Open Label Phase

A randomized, open-label, Phase III trial of pertuzumab retreatment in HER2-positive locally advanced/metastatic breast cancer patients previously treated with pertuzumab, trastuzumab and chemotherapy: the Japan Breast Cancer Research Group-M05 PRECIOUS study

Japanese Journal of Clinical Oncology ◽

10.1093/jjco/hyy097 ◽

2018 ◽

Vol 48 (9) ◽

pp. 855-859 ◽

Cited By ~ 2

Author(s):

Yutaka Yamamoto ◽

Hiroji Iwata ◽

Takayuki Ueno ◽

Naruto Taira ◽

Masahiro Kashiwaba ◽

...

Keyword(s):

Breast Cancer ◽

Locally Advanced ◽

Metastatic Breast ◽

Phase Iii ◽

Breast Cancer Patients ◽

Her2 Positive ◽

Open Label ◽

Phase Iii Trial ◽

Open Label Phase ◽

Previously Treated

Abstract PD3-11: A randomized, open-label, phase III trial of pertuzumab re-treatment in HER2-positive, locally advanced/metastatic breast cancer patients previously treated with pertuzumab, trastuzumab, and chemotherapy: The Japan Breast Cancer Research Group-M05 (PRECIOUS) study

10.1158/1538-7445.sabcs20-pd3-11 ◽

2021 ◽

Author(s):

Yutaka Yamamoto ◽

Hiroji Iwata ◽

Taira Naruto ◽

Norikazu Masuda ◽

Masato Takahashi ◽

...

Keyword(s):

Breast Cancer ◽

Locally Advanced ◽

Metastatic Breast ◽

Phase Iii ◽

Breast Cancer Patients ◽

Her2 Positive ◽

Open Label ◽

Phase Iii Trial ◽

Open Label Phase ◽

Previously Treated

Abstract OT2-05-01: FAMILY: A randomized, multicenter, open-label, phase III trial of fulvestrant versus capecitabine as maintenance therapy after first-line combination chemotherapy in patients with hormone receptor-positive, human epidermal growth factor receptor-2 negative metastatic breast cancer

10.1158/1538-7445.sabcs18-ot2-05-01 ◽

2019 ◽

Author(s):

H Yao ◽

W Wu ◽

L Ding ◽

Y Yu ◽

Y Wang ◽

...

Keyword(s):

Breast Cancer ◽

Growth Factor Receptor ◽

Metastatic Breast ◽

Phase Iii ◽

First Line ◽

Open Label ◽

Phase Iii Trial ◽

Hormone Receptor Positive ◽

Open Label Phase ◽

Epidermal Growth

PRECIOUS: A randomized, open-label phase III trial of pertuzumab retreatment in HER2-positive locally advanced/metastatic breast cancer patients who were previously treated with pertuzumab, trastuzumab, and chemotherapy.

Journal of Clinical Oncology ◽

10.1200/jco.2016.34.15_suppl.tps636 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. TPS636-TPS636

Author(s):

Yutaka Yamamoto ◽

Hiroji Iwata ◽

Takayuki Ueno ◽

Masahiro Kashiwaba ◽

Naruto Taira ◽

...

Keyword(s):

Breast Cancer ◽

Locally Advanced ◽

Metastatic Breast ◽

Phase Iii ◽

Breast Cancer Patients ◽

Her2 Positive ◽

Open Label ◽

Phase Iii Trial ◽

Open Label Phase ◽

Previously Treated

179TiP EMERALD: A randomized, open-label, phase III trial to evaluate the efficacy and safety of elacestrant (RAD1901), a novel oral selective estrogen receptor degrader (SERD), vs investigator’s choice of endocrine therapy for ER+/HER2- advanced breast cancer following CDK4/6 inhibitor therapy

Annals of Oncology ◽

10.1016/j.annonc.2020.03.279 ◽

2020 ◽

Vol 31 ◽

pp. S80

Author(s):

A. Bardia ◽

J. Lu ◽

V. Kaklamani ◽

J. Jung ◽

A.T. Anderson-Villaluz ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Advanced Breast Cancer ◽

Endocrine Therapy ◽

Inhibitor Therapy ◽

Phase Iii ◽

Efficacy And Safety ◽

Open Label ◽

Phase Iii Trial ◽

Open Label Phase

A randomised two-arm, prospective, multi-centre, open-label phase III trial comparing the activity and safety of a weekly versus a three-weekly paclitaxel treatment schedule in patients with advanced or metastatic breast cancer

http://isrctn.org/> ◽

10.1186/isrctn52817670 ◽

2012 ◽

Author(s):

M Verrill

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Metastatic Breast ◽

Phase Iii ◽

Weekly Paclitaxel ◽

Treatment Schedule ◽

Open Label ◽

Phase Iii Trial ◽

Open Label Phase ◽

Paclitaxel Treatment

Abstract LB-177: First-line bevacizumab (BEV) + chemotherapy for hormone receptor-positive metastatic breast cancer (mBC): Subgroup analysis of the open-label non-inferiority TURANDOT phase III trial.

10.1158/1538-7445.am2013-lb-177 ◽

2013 ◽

Author(s):

Zsuzsanna Kahán ◽

Lubos Petruzelka ◽

Alexandru Eniu ◽

Rodica Anghel ◽

Krassimir Koynov ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Subgroup Analysis ◽

Hormone Receptor ◽

Metastatic Breast ◽

Phase Iii ◽

First Line ◽

Open Label ◽

Phase Iii Trial ◽

Hormone Receptor Positive